Propranolol

Etki Mekanizması

Propranolol competitively blocks both beta-1 and beta-2 adrenergic receptors. Beta-1 blockade in the sinoatrial node and myocardium reduces heart rate (negative chronotropy), decreases the force of cardiac contraction (negative inotropy), and slows atrioventricular conduction (negative dromotropy). This directly counteracts the tachycardia induced by sympathomimetic compounds like clenbuterol and the unexplained heart rate elevation commonly reported with trenbolone use. Beta-2 blockade in peripheral vasculature contributes to a modest increase in peripheral vascular resistance initially, though chronic use leads to a net reduction in blood pressure through decreased cardiac output and suppression of renin release from the juxtaglomerular cells. Propranolol is highly lipophilic, readily crossing the blood-brain barrier, which accounts for its efficacy in managing anxiety symptoms, essential tremor, and the physical manifestations of sympathetic nervous system activation (tremor, palpitations, sweating). This central penetration also explains why propranolol is more effective for anxiety-related indications than hydrophilic beta blockers like atenolol. The drug undergoes extensive first-pass hepatic metabolism via CYP2D6 and CYP1A2, resulting in variable bioavailability (approximately 25-35%).